After a decade of stagnation in drug development, therapeutic reversal of immune‐
exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in …

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …

The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide. The
onset of the disease is occult and develops rapidly. As a result, the disease is often detected …

Simple Summary Immune checkpoint inhibitors represent a promising treatment choice in
many kind of tumours, including hepatocellular carcinoma (HCC). In this review, we provide …

In advanced-stage hepatocellular carcinoma (HCC), systemic treatment represents the
standard therapy. Target therapy has marked a new era based on a greater knowledge of …

Simple Summary Immune checkpoint inhibitor (ICI) therapy has recently become the
standard treatment for advanced hepatocellular carcinoma (HCC); however, clinical …

Hepatocellular carcinoma (HCC) is the most common malignancy worldwide, and is
especially common in China. A total of 70%–80% of patients are diagnosed at an advanced …

Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …

After years of in-depth research on immune checkpoints, therapeutic reversal of immune-
exhaustion with immune checkpoint inhibitors (ICPIs) has been shown to be effective in …